title: Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
abstract: OBJECTIVE
  We evaluated efficacy and toxicity of weekly paclitaxel in metastatic hormone-refractory prostate cancer (HRPC).
  
  
  METHODS
  Patients received weekly paclitaxel 80 mg/m2 by 1-hour intravenous infusion. A course of therapy consisted of 6 weekly treatments and 2 weeks rest. PSA response was defined as a PSA decrease not less than 50%, maintained for 4 weeks with stable or improved performance status.
  
  
  RESULTS
  The study enrolled 43 patients with metastatic HRPC diagnosed a median of 10.5 months before. Median age was 69 years (range, 58-86 years). Five had previous radioisotopes treatment for bone pain, 15 had previous treatment of metastatic hormone-refractory disease, mainly estramustine. The median number of weeks of therapy delivered each patient was 8 (range, 1-24 weeks; cumulative, 369 weeks). PSA response was registered in 13 patients of 36 evaluable for PSA response (36.1%; 95% confidence interval [CI], 20.8-53.8), with a median duration of 4.2 months. Among 16 patients evaluable for objective response, 5 partial responses (31.2%; 95% CI, 11.0-58.7) and 9 stable diseases were registered. Eleven (42.3%) of 26 patients presenting with cancer-related symptoms had improvement. Median survival time was 12.8 months (95% CI, 10.1-15.5) Therapy was associated with acceptable hematological toxicity (anemia grade 3, 16%; neutropenia grade 3-4, 12%) and moderate nonhematologic toxicities (thrombosis/embolism 10%; fatigue all grades, 60%).
  
  
  CONCLUSIONS
  Docetaxel every 3 weeks is the standard of care for metastatic HRPC, but our results suggest some activity and an acceptable toxicity of weekly paclitaxel.
authors.affiliation: Centro Oncologico ed Ematologico Subalpino, Azienda Ospedaliera San Giovanni Battista, Corso Bramante 88, 10126 Torino, Italy. ichiapp@tin.it
authors.forename: Isabella
authors.initials: I
authors.lastname: Chiappino
authors.forename: Paolo
authors.initials: P
authors.lastname: Destefanis
authors.forename: Alfredo
authors.initials: A
authors.lastname: Addeo
authors.forename: Alessandra
authors.initials: A
authors.lastname: Galetto
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Cucchiarale
authors.forename: Fernando
authors.initials: F
authors.lastname: Munoz
authors.forename: Andrea
authors.initials: A
authors.lastname: Zitella
authors.forename: Ugo
authors.initials: U
authors.lastname: Ferrando
authors.forename: Dario
authors.initials: D
authors.lastname: Fontana
authors.forename: Umberto
authors.initials: U
authors.lastname: Ricardi
authors.forename: Alessandro
authors.initials: A
authors.lastname: Tizzani
authors.forename: Oscar
authors.initials: O
authors.lastname: Bertetto
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel